Strategic Collaborative

 
News Articles for Strategic Collaborative top ^
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) and AbbVie Inc. (NYSE: ABBV) today announced that they have entered into a global collaboration to develop and commercialize duvelisib (IPI-145), Infinity’s oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, for the treatment of patients with cancer.
Sign-up for Infinity and AbbVie Announce Global Strategic Collaboration to Develop and Commercialize Duvelisib (IPI-145) In Oncology investment picks
- Infinity to Receive $275 Million Upfront Payment and $530 Million in Potential Milestones - - Companies to Jointly Develop and Commercialize Duvelisib in U.S., with Equal Profit Share; Infinity to Receive Royalties on Sales Outside the U.S. - - Infinity to Host Conference Call Today at 8:30 A.M. ET/7:30 A.M. CT - CAMBRIDGE, Mass.
Sign-up for Infinity And AbbVie Announce Global Strategic Collaboration To Develop And Commercialize Duvelisib (IPI-145) In Oncology investment picks
NANJING , China , July 7, 2014 /PRNewswire/ -- China Sunergy Co., Ltd.
Sign-up for China Sunergy Signs Strategic Collaboration Agreement with the 48th Research Institute of China Electronics Technology Group Corporation investment picks
-- Largest ISV in Asia Pacific to port its leading enterprise management software to IBM's DB2 platform --
Sign-up for IBM And Yonyou Announce Strategic Collaboration To Accelerate Big Data And Analytics Adoption investment picks
Service Will Feature Blockbuster Lionsgate Films Such As Divergent and The Twilight Saga: Eclipse and Premium TV Programming Including Mad Men, Weeds, Nashville, The Royals and Rosemary's Baby HANGZHOU, China and SANTA MONICA, Calif.
Sign-up for LIONSGATE AND ALIBABA GROUP FORM STRATEGIC COLLABORATION TO OFFER LIONSGATE ENTERTAINMENT WORLD SERVICE IN CHINA investment picks
2014/7/3
- Dermira obtains exclusive rights to develop Cimzia® in psoriasis in the US, Canada and the European Union - Driven by positive Phase 2 results with Cimzia® in psoriasis and the Phase 3 results in psoriatic arthritis(1,2) - Subject to regulatory approval in psoriasis, Dermira is granted exclusive rights to market Cimzia® to dermatologists in the US and Canada BRUSSELS and REDWOOD CITY, Calif.
Sign-up for UCB and Dermira enter into strategic collaboration in dermatology to broaden patient access to Cimzia® (certolizumab pegol) investment picks

Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Strategic Collaborative
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Strategic Assets  |  Next: Strategic Cooperation